{"id":"https://openalex.org/W13210705","doi":null,"title":"Pharmacokinetics and drug interactions: update for new antipsychotics.","display_name":"Pharmacokinetics and drug interactions: update for new antipsychotics.","publication_year":1996,"publication_date":"1996-01-01","ids":{"openalex":"https://openalex.org/W13210705","mag":"13210705","pmid":"https://pubmed.ncbi.nlm.nih.gov/8941167"},"language":"en","primary_location":{"id":"pmid:8941167","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8941167","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical psychiatry","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5009531510","display_name":"Larry Ereshefsky","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I165951966","display_name":"The University of Texas at San Antonio Health Science Center","ror":"https://ror.org/02f6dcw23","country_code":"US","type":"education","lineage":["https://openalex.org/I165951966","https://openalex.org/I45438204"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"L Ereshefsky","raw_affiliation_strings":["Department of Pharmacology, University of Texas Health Science Center at San Antonio 78284-6220, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Pharmacology, University of Texas Health Science Center at San Antonio 78284-6220, USA","institution_ids":["https://openalex.org/I165951966"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5009531510"],"corresponding_institution_ids":["https://openalex.org/I165951966"],"apc_list":null,"apc_paid":null,"fwci":13.2961,"has_fulltext":false,"cited_by_count":211,"citation_normalized_percentile":{"value":0.99649562,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"57 Suppl 11","issue":null,"first_page":"12","last_page":"25"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.7509999871253967,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.7509999871253967,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10023","display_name":"Schizophrenia research and treatment","score":0.24379999935626984,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12547","display_name":"Pharmaceutical studies and practices","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antipsychotic-drugs","display_name":"antipsychotic drugs","score":0.8050000071525574},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.968999981880188},{"id":"https://openalex.org/keywords/drug-drug-interactions","display_name":"drug-drug interactions","score":0.9129999876022339},{"id":"https://openalex.org/keywords/schizophrenia","display_name":"schizophrenia","score":0.7910000085830688},{"id":"https://openalex.org/keywords/clozapine","display_name":"clozapine","score":0.878000020980835},{"id":"https://openalex.org/keywords/olanzapine","display_name":"olanzapine","score":1.0},{"id":"https://openalex.org/keywords/sertindole","display_name":"sertindole","score":0.996999979019165},{"id":"https://openalex.org/keywords/risperidone","display_name":"risperidone","score":1.0},{"id":"https://openalex.org/keywords/cyp2d6-polymorphism","display_name":"CYP2D6 polymorphism","score":0.7960000038146973},{"id":"https://openalex.org/keywords/cyp3a-inhibition","display_name":"CYP3A inhibition","score":0.9269999861717224},{"id":"https://openalex.org/keywords/n-glucuronidation","display_name":"N-glucuronidation","score":0.8169999718666077},{"id":"https://openalex.org/keywords/flavin-containing-monooxygenase","display_name":"flavin-containing monooxygenase","score":0.8989999890327454},{"id":"https://openalex.org/keywords/atypical-antipsychotics","display_name":"atypical antipsychotics","score":0.7310000061988831},{"id":"https://openalex.org/keywords/negative-symptoms","display_name":"negative symptoms","score":0.5540000200271606},{"id":"https://openalex.org/keywords/extrapyramidal-symptoms","display_name":"extrapyramidal symptoms","score":0.8899999856948853},{"id":"https://openalex.org/keywords/dose-optimization","display_name":"dose optimization","score":0.5640000104904175},{"id":"https://openalex.org/keywords/interpatient-variability","display_name":"interpatient variability","score":0.5839999914169312}],"concepts":[{"id":"https://openalex.org/C2780777758","wikidata":"https://www.wikidata.org/wiki/Q418050","display_name":"Sertindole","level":4,"score":0.8909705877304077},{"id":"https://openalex.org/C2776619155","wikidata":"https://www.wikidata.org/wiki/Q201872","display_name":"Olanzapine","level":3,"score":0.8350957036018372},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.729832649230957},{"id":"https://openalex.org/C2780864610","wikidata":"https://www.wikidata.org/wiki/Q221361","display_name":"Clozapine","level":3,"score":0.6968817710876465},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6741330027580261},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.6006903648376465},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.566479504108429},{"id":"https://openalex.org/C2780494398","wikidata":"https://www.wikidata.org/wiki/Q208144","display_name":"Antipsychotic","level":3,"score":0.5618562698364258},{"id":"https://openalex.org/C2780057945","wikidata":"https://www.wikidata.org/wiki/Q412443","display_name":"Risperidone","level":3,"score":0.47072258591651917},{"id":"https://openalex.org/C2779907587","wikidata":"https://www.wikidata.org/wiki/Q14901439","display_name":"Glucuronidation","level":4,"score":0.4663993716239929},{"id":"https://openalex.org/C89311334","wikidata":"https://www.wikidata.org/wiki/Q1124842","display_name":"Drug metabolism","level":3,"score":0.45857101678848267},{"id":"https://openalex.org/C2780948584","wikidata":"https://www.wikidata.org/wiki/Q251347","display_name":"Haloperidol","level":3,"score":0.42589738965034485},{"id":"https://openalex.org/C2776921671","wikidata":"https://www.wikidata.org/wiki/Q758295","display_name":"Atypical antipsychotic","level":4,"score":0.417997270822525},{"id":"https://openalex.org/C2776412080","wikidata":"https://www.wikidata.org/wiki/Q7431605","display_name":"Schizophrenia (object-oriented programming)","level":2,"score":0.3358295261859894},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.19099634885787964},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.17171207070350647},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.16743233799934387},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.1669977903366089},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C87644729","wikidata":"https://www.wikidata.org/wiki/Q547502","display_name":"Microsome","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004347","descriptor_name":"Drug Interactions","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006207","descriptor_name":"Half-Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012559","descriptor_name":"Schizophrenia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012565","descriptor_name":"Schizophrenic Psychology","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D014150","descriptor_name":"Antipsychotic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:8941167","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8941167","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The Journal of clinical psychiatry","raw_type":"Journal Article"},{"id":"mag:13210705","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/8941167","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.98580002784729,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W7097467757","https://openalex.org/W2096739998","https://openalex.org/W2099767837","https://openalex.org/W2068485725","https://openalex.org/W2118205890","https://openalex.org/W2117968101","https://openalex.org/W2021087332","https://openalex.org/W7096639800","https://openalex.org/W2086678987","https://openalex.org/W3179536018"],"abstract_inverted_index":{"Advances":[0],"in":[1,33,56,112,243,251,267],"our":[2],"understanding":[3],"of":[4,12,38,42,44,61,76,162,207,224,239,270],"schizophrenia":[5],"have":[6],"led":[7],"to":[8,170,198,237],"a":[9,93,129,196,204],"new":[10],"generation":[11],"antipsychotic":[13],"agents.":[14],"These":[15],"medications":[16],"not":[17,235],"only":[18,195],"demonstrate":[19,194,212],"reduced":[20],"extrapyramidal":[21],"symptoms":[22,37],"but":[23],"also":[24,66],"possess":[25],"pharmacologic":[26],"profiles":[27],"that":[28,172],"can":[29],"be":[30,238],"especially":[31],"advantageous":[32],"treating":[34],"the":[35,45,57,62,74,77,88,150,217],"negative":[36],"schizophrenia.":[39],"The":[40,159,221],"pharmacokinetics":[41,58],"many":[43,103],"newer":[46,63,78],"agents":[47,64,79],"are":[48,65,232,254],"compared":[49],"and":[50,59,80,102,115,123,210,229,234,262],"contrasted":[51],"with":[52,97],"typical":[53],"neuroleptics.":[54],"Changes":[55],"dosage":[60],"reviewed.":[67],"A":[68],"particular":[69],"emphasis":[70],"is":[71],"placed":[72],"on":[73],"metabolism":[75,179,214],"their":[81],"potential":[82,132],"for":[83,120,133],"drug-drug":[84,105,134],"pharmacokinetic":[85,95],"interactions.":[86,106],"Clozapine,":[87],"archetypal":[89],"atypical":[90],"agent,":[91],"has":[92],"complex":[94],"profile":[96],"extremely":[98,138],"large":[99],"interpatient":[100],"variability":[101,200],"well-documented":[104],"Thus,":[107],"clozapine":[108],"presents":[109],"special":[110],"challenges":[111],"dose":[113,206],"optimization":[114],"requires":[116,137],"vigilant":[117],"clinical":[118,240],"monitoring":[119],"cardiovascular,":[121],"neurologic,":[122],"hematologic":[124],"adverse":[125],"effects.":[126],"Olanzapine":[127],"demonstrates":[128],"very":[130],"low":[131],"interactions;":[135],"it":[136],"high":[139],"inhibitory":[140,222],"concentrations":[141,152,189,258],"at":[142,154,190,203,226],"cytrochrome":[143],"P450":[144],"(CYP)":[145],"systems,":[146],"typically":[147,193],"30-fold":[148],"above":[149],"usual":[151],"observed":[153],"steady-state":[155],"oral":[156],"high-dose":[157],"therapy.":[158],"metabolic":[160],"pathways":[161],"olanzapine":[163,188],"include":[164],"N-glucuronidation,":[165],"reducing":[166],"its":[167,177,263],"overall":[168],"sensitivity":[169],"drugs":[171],"might":[173,265],"induce":[174],"or":[175,182,250],"inhibit":[176],"own":[178],"via":[180],"CYP":[181,218,227,230,247,271],"flavin-containing":[183],"monooxygenase":[184],"(FMO)":[185],"systems.":[186],"Plasma":[187],"steady":[191],"state":[192],"fourfold":[197],"fivefold":[199],"among":[201],"patients":[202,245],"standard":[205],"medications.":[208],"Sertindole":[209],"risperidone":[211],"polymorphic":[213],"characteristics":[215],"mirroring":[216],"2D6":[219,228,248],"phenotype.":[220],"potentials":[223],"sertindole":[225,261],"3A":[231],"modest":[233],"likely":[236],"significance.":[241],"However,":[242],"those":[244,252],"taking":[246],"inhibitors":[249],"who":[253],"genotypic":[255],"poor":[256],"metabolizers,":[257],"achieved":[259],"by":[260],"metabolites":[264],"result":[266],"moderate":[268],"inhibition":[269],"3A.":[272]},"counts_by_year":[{"year":2025,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":4},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":3},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":6},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}